Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SoftOx Solutions ASFRA:6FV EV-to-EBIT is -21.15 as of Aug. 18, 2026. Among 370 Biotechnology companies, SoftOx Solutions AS ranks worse than 270270% on this metric.
SoftOx Solutions AS (FRA:6FV) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SoftOx Solutions AS's Enterprise Value for the quarter that ended in Dec. 2025 was €11.14 Mil.
SoftOx Solutions AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SoftOx Solutions AS EV-to-EBIT Related Terms
SoftOx Solutions AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SoftOx Solutions AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6FV vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, SoftOx Solutions AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SoftOx Solutions AS EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SoftOx Solutions AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SoftOx Solutions AS's EV-to-EBIT falls into.
SoftOx Solutions AS's current Enterprise Value is €20.54 Mil.
SoftOx Solutions AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SoftOx Solutions AS (FRA:6FV) has a EV-to-EBIT of -21.15 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SoftOx Solutions AS and its competitors. According to the industry distribution chart, SoftOx Solutions AS ranks #999999 out of 370 companies in the Biotechnology industry.
Is SoftOx Solutions AS's EV-to-EBIT too high?
SoftOx Solutions AS's current EV-to-EBIT is -21.15. Based on the distribution chart, SoftOx Solutions AS ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does SoftOx Solutions AS's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SoftOx Solutions AS ranks #999999 out of 370 companies for EV-to-EBIT. This places SoftOx Solutions AS in the lower half of its industry. The industry median EV-to-EBIT is 16.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SoftOx Solutions AS and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SoftOx Solutions AS's current EV-to-EBIT is -21.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SoftOx Solutions AS stock overvalued right now?
SoftOx Solutions AS (FRA:6FV) has a current EV-to-EBIT of -21.15. The current EV-to-EBIT is -21.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SoftOx Solutions AS (FRA:6FV), the current EV-to-EBIT is -21.15 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SoftOx Solutions AS is a clinical-stage pharmaceutical company. It offers antimicrobial solutions for Wound and Skin Care. It has developed an effective antimicrobial solution to combat biofilm, viral, and antimicrobial-resistant infections. The technology is based on extensive research and development in partnership with Nordic research institutes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FV has been successfully added to your 
